A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DAMB / deoxycholate amphotericin B

[Related PubMed/MEDLINE]
Total Number of Papers: 25
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DAMB  (>> Co-occurring Abbreviation)
Long Form:   deoxycholate amphotericin B
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
1  2021 Activity of Amphotericin B Formulations and Voriconazole, Alone or in Combination, against Biofilms of Scedosporium and Fusarium spp. FSSC, L-AmB, VRC
2  2019 Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles. AmB, CL, IL
3  2013 Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice. DMSA, PLGA
4  2012 Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity. L-AmB
5  2010 Comparative study of the efficacy of liposomal amphotericin B and amphotericin B deoxycholate against six species of Zygomycetes in a murine lethal infection model. L-AmB, MTD
6  2010 [In vivo activity of liposomal amphotericin B against Exophiala dermatitidis in a murine lethal infection model]. L-AmB
7  2009 Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis. BUN, DMSA, i.p, PLGA
8  2008 Microarray analysis of amphotericin B-treated THP-1 monocytic cells identifies unique gene expression profiles among lipid and non-lipid drug formulations. ABCD, ABLC
9  2007 Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. ABLC, AmB, CM
10  2006 Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani. ABLC, PAMs
11  2006 Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus. ABCD, DIIs, L-AmB, MNCs
12  2006 Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis. GMI, IPA, MDVI, UC, UFCT
13  2005 Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. ABCD, ABLC, IL-1beta, IL-1ra, L-AmB, MCP-1, MIP-1beta, MNCs, TNF-alpha
14  2005 [Diagnosis and management of fungal infections and pneumocystis pneumonitis in pediatric cancer patients]. CAS, FLC, G-CSF, GPOH, IDSA, L-AmB, VCZ
15  2004 Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. FLC, i.v, OPEC
16  2003 Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. L-AmB
17  2002 Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. ABLC
18  2002 Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. L-AmB, UCs
19  2000 Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits. ABLC
20  1997 Efficacy of deoxycholate amphotericin B and unilamellar liposomal amphotericin B in prophylaxis of experimental Aspergillus fumigatus endocarditis. L-AmB
21  1996 Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. IL
22  1994 Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. ABCD
23  1994 In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. ---
24  1994 Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. LAmB
25  1992 Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses. ---